Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AdaptHealth Corp.AHCO · Entity 5183 | Director | August 06, 2026 | August 11, 2026 |
| Evolent Health, Inc.EVH · Entity 5492 | Director | August 15, 2019 | August 19, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AdaptHealth Corp.
Report date August 06, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,569 |
Reported balance
After 2026-08-06 transaction · row 1
1 source rowRow 1 · 2026-08-06 · Purchase · Acquired 23,500 · Balance 48,569 |
Evolent Health, Inc.
Report date August 15, 2019 · Filed August 19, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 39,235 |
Reported balance
After 2019-08-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-08-15 · Purchase · Acquired 7,200 · Balance 39,235 F1: The price reported in Column 4 is a weighted average. These shares were purchased in multiple transactions at prices ranging from $7.03-$7.05, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average. These shares were purchased in multiple transactions at prices ranging from $7.03-$7.05, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
COGENTIX MEDICAL INC /DE/
Report date April 20, 2018 · Filed April 23, 2018
Section 16 reporting ended · disclosed 2018-04-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-04-20 transaction · row 1
1 source rowRow 1 · 2018-04-20 · Other · Disposed 184,172 · Balance 0 F1: On April 20, 2018, these shares were purchased in a tender offer for all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") by Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC, pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement"). |
Filing footnotes · ownership attribution and instrument terms
F1: On April 20, 2018, these shares were purchased in a tender offer for all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") by Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC, pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement").
LUMINEX CORP
Report date July 14, 2021 · Filed July 15, 2021
Section 16 reporting ended · disclosed 2021-07-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,817 |
Reported balance
After 2021-07-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-07-14 · Disposition to issuer · Disposed 3,000 · Balance 16,817 F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share. F2: This total includes 197 dividend equivalent shares acquired from the Issuer as follows: 29 shares on 07/09/20, 45 shares on 10/15/20, 43 shares on 01/14/21, 34 shares on 04/15/21, and 46 shares on 07/08/21. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-07-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2021-07-14 · Disposition to issuer · Disposed 16,817 · Balance 0 F3: Disposed of pursuant to the Merger Agreement, whereby unvested restricted stock units ("Company RSUs") which were outstanding as of immediately prior to the Effective Time fully vested, and each Company RSU that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share.
F2: This total includes 197 dividend equivalent shares acquired from the Issuer as follows: 29 shares on 07/09/20, 45 shares on 10/15/20, 43 shares on 01/14/21, 34 shares on 04/15/21, and 46 shares on 07/08/21.
F3: Disposed of pursuant to the Merger Agreement, whereby unvested restricted stock units ("Company RSUs") which were outstanding as of immediately prior to the Effective Time fully vested, and each Company RSU that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 11, 2026 00:03 UTC | AdaptHealth Corp. AHCO · Entity 5183 | PurchaseCommon Stock | 23,500 | $6.38 | $149,930.00 |
DisclosureSEC source: 0001104659-26-093576 · tm2622716-2_4seq1.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,569 Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:04 UTC | AdaptHealth Corp. AHCO · Entity 5183 | GrantCommon Stock | 6,070 | $9.89 | $60,032.30 |
DisclosureSEC source: 0001104659-26-078238 · tm2619030-2_4seq1.xml · nonDerivative · entry 2 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,069 F1 · shares: These shares represent restricted stock units and will be settled in common stock upon vesting. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 20:04 UTC | AdaptHealth Corp. AHCO · Entity 5183 | GrantCommon Stock | 18,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-078238 · tm2619030-2_4seq1.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,999 F1 · shares: These shares represent restricted stock units and will be settled in common stock upon vesting. Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 16:03 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerCommon Stock | 16,817 | $37.00 | $622,229.00 |
DisclosureSEC source: 0001033905-21-000064 · wf-form4_162637940379534.xml · nonDerivative · entry 2 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · shares: Disposed of pursuant to the Merger Agreement, whereby unvested restricted stock units ("Company RSUs") which were outstanding as of immediately prior to the Effective Time fully vested, and each Company RSU that was outstanding immediately prior to the Effective Time was canceled at the Effective Time, in exchange for cash payments in the amount of $37.00 per share (without interest and subject to deduction for any required withholding taxes). Read SEC document |
| July 14, 2021 Filed Jul 15, 2021 16:03 UTC | LUMINEX CORP LMNX · Entity 137318 | Disposition to issuerCommon Stock | 3,000 | $37.00 | $111,000.00 |
DisclosureSEC source: 0001033905-21-000064 · wf-form4_162637940379534.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,817 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, by and among DiaSorin S.p.A., Diagonal Subsidiary Inc. and Luminex Corporation (the "Issuer"), dated April 11, 2021 (the "Merger Agreement"), whereby each outstanding share of the Issuer's common stock was cancelled at the effective time (the "Effective Time") of the merger (the "Merger") and converted into the right to receive a cash payment of $37.00 per share. F2 · balance_after: This total includes 197 dividend equivalent shares acquired from the Issuer as follows: 29 shares on 07/09/20, 45 shares on 10/15/20, 43 shares on 01/14/21, 34 shares on 04/15/21, and 46 shares on 07/08/21. Read SEC document |
| June 01, 2020 Filed Jun 2, 2020 18:34 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantCommon Stock | 5,652 | $0.00 | $0.00 |
DisclosureSEC source: 0001033905-20-000067 · wf-form4_159113723145126.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,620 F1 · balance_after: This total includes 39 dividend shares acquired as follows: 2 shares on 07/11/19, 6 shares on 10/17/19, 16 shares on 01/15/20, and 15 shares on 04/09/20. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 20:06 UTC | Evolent Health, Inc. EVH · Entity 5492 | PurchaseClass A Common Stock | 7,200 | $7.04 | $50,688.00 |
DisclosureSEC source: 0001628908-19-000062 · primary_doc.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,235 F1 · price: The price reported in Column 4 is a weighted average. These shares were purchased in multiple transactions at prices ranging from $7.03-$7.05, inclusive. The reporting person undertakes to provide to Evolent Health, Inc., any security holder of Evolent Health, Inc., or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: Includes restricted stock units granted under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 12:19 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantClass A Common Stock | 14,156 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-19-000044 · primary_doc.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,035 F1 · security: Represents restricted stock units granted to Mr. Samet pursuant to the Evolent Health, Inc. Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 11, 2020 and the date of the company's 2020 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 17, 2019 Filed May 20, 2019 18:38 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantCommon Stock | 8,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001033905-19-000052 · wf-form4_155839191932291.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,929 Read SEC document |
| January 31, 2019 Filed Feb 6, 2019 14:14 UTC | LUMINEX CORP LMNX · Entity 137318 | GrantCommon Stock | 2,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001033905-19-000007 · wf-form4_154948044047824.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,622 Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 21:15 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantClass A Common Stock | 5,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001628908-18-000048 · primary_doc.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,879 F1 · security: Represents restricted stock units granted to Mr. Samet pursuant to the Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 13, 2019 and the date of the company's 2019 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| April 20, 2018 Filed Apr 23, 2018 17:10 UTC | COGENTIX MEDICAL INC /DE/ CGNT · Entity 167360 | OtherCommon Stock | 184,172 | $3.85 | $709,062.20 |
DisclosureSEC source: 0001437749-18-007493 · rdgdoc.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: On April 20, 2018, these shares were purchased in a tender offer for all of the issued and outstanding shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (the Company") by Camden Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of LM US Parent, Inc. and Laborie Medical Technologies Canada ULC, pursuant to the Agreement and Plan of Merger dated as of March 11, 2018 (the "Merger Agreement"). Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:30 UTC | Evolent Health, Inc. EVH · Entity 5492 | GrantClass A Common Stock | 4,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001359252-17-000002 · primary_doc.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,420 F1 · security: Represents restricted stock units granted to Mr. Samet pursuant to Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan. F2 · shares: Securities vest on the earlier of June 8, 2018 and the date of the company's 2018 annual meeting, subject to the reporting person's continued service on the vesting date. F3 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 21:03 UTC | Evolent Health, Inc. EVH · Entity 5492 | SaleClass A Common Stock | 4,000 | $25.75 | $103,000.00 |
DisclosureSEC source: 0001359252-17-000001 · primary_doc.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,850 F1 · balance_after: Includes restricted stock units under awards reported on Table 1 of Form 4s previously filed with the Securities and Exchange Commission. Read SEC document |
| May 23, 2017 Filed May 24, 2017 17:17 UTC | COGENTIX MEDICAL INC /DE/ CGNT · Entity 167360 | GrantCommon Stock | 59,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-009999 · rdgdoc.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,172 F1 · shares: Restricted Stock Award vests in full six months from the date of grant. F2 · balance_after: Total holdings include restricted stock awards. Read SEC document |
| November 18, 2016 Filed Nov 21, 2016 17:05 UTC | COGENTIX MEDICAL INC /DE/ CGNT · Entity 167360 | PurchaseCommon Stock | 25,000 | $2.47 | $61,727.50 |
DisclosureSEC source: 0001437749-16-042477 · rdgdoc.xml · nonDerivative · entry 1 SAMET KENNETH A · CIK 0001359252 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 F1 · price: The price reported is the weighted average purchase price for the transactions reported. The prices paid ranged from $2.41 to $2.48. The Reporting Person will provide to the issuer, a security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.